Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...
Pharmaceutical Technology on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn projected consensus 2028 Keytruda sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results